Pfizer Limited PFIZER NIFTY_SMALLNSEPHARMA
Company Overview
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers therapy area and products, such as vaccines, injectables and anti-infectives, inflammation and immunology, and internal medicine for cardiovascular care, oncology, respiratory, multivitamins and multimineral, neuroscience, women's health, gastroenterology, pain management, and nutrition, addressing. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.
Why Investors Should Care
Generates a return on equity of 17.2%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 22.9%.
Trades at a P/E of 29.8, below the sector median of 40.0.
Maintains a net profit margin of 28.7%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹2,519.27 Cr (+10.4% YoY); net profit ₹722.43 Cr.
- Trailing 12 Months Year-on-year growth — revenue +10.4%, earnings -5.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 1.3%, profit CAGR 5.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 1.32% |
| 1 Year: | 10.45% |
Compounded Profit Growth
| 5 Years: | 5.01% |
| 1 Year: | -5.88% |
Stock Price Performance
| 1 Year: | -13.90% |
| 6 Months: | -1.94% |
| 3 Months: | -3.73% |
| 1 Month: | +4.32% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)62.28 · Neutral
P/E of 29.84 is below the sector median of 39.97 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 22.9%.
- Excellent profit margin of 28.7%.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PFIZER Pfizer Limited NIFTY_SMALLNSEPHARMA | 4,713.00 | 29.84 | ₹21,560.91 Cr | 1.59% | 22.94% | 17.19% | 1.32% | 5.01% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,948.80 | 40.77 | ₹4.68 L Cr | 0.83% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 7,315.50 | 75.61 | ₹1.94 L Cr | 0.44% | 18.96% | 15.32% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,952.20 | 87.70 | ₹1.68 L Cr | 0.78% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,981.00 | 66.51 | ₹1.29 L Cr | 0.23% | 19.79% | 20.48% | 15.33% | 33.34% |
| 6 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,440.10 | 22.07 | ₹1.16 L Cr | 0.90% | 14.86% | 11.27% | 7.23% | 11.45% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,137.40 | 22.71 | ₹1.14 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,494.30 | 21.42 | ₹1.14 L Cr | 0.72% | 28.42% | 23.76% | 19.10% | 131.46% |
| 9 | MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA | 1,099.00 | 99.82 | ₹1.07 L Cr | 0.18% | 12.57% | 13.42% | 22.37% | 9.34% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 591.91 Cr | 603.05 Cr | 642.34 Cr | 645.03 Cr | 629.23 Cr |
| Cost of Revenue | 202.48 Cr | 211.23 Cr | 227.95 Cr | 224.77 Cr | 220.36 Cr |
| Gross Profit | 389.43 Cr | 391.82 Cr | 414.39 Cr | 420.26 Cr | 408.87 Cr |
| Operating Expenses | 178.33 Cr | 196.21 Cr | 198.74 Cr | 206.33 Cr | 187.70 Cr |
| Operating Income | 211.10 Cr | 195.61 Cr | 215.65 Cr | 213.93 Cr | 221.17 Cr |
| EBITDA | 444.89 Cr | 277.19 Cr | 271.78 Cr | 208.20 Cr | 285.71 Cr |
| Interest Expense | 2.69 Cr | 3.25 Cr | 2.13 Cr | 1.99 Cr | 2.11 Cr |
| Pretax Income | 425.80 Cr | 259.53 Cr | 255.37 Cr | 191.95 Cr | 268.82 Cr |
| Tax Provision | 94.86 Cr | 67.78 Cr | 66.35 Cr | 50.11 Cr | 69.00 Cr |
| Net Income | 330.94 Cr | 191.75 Cr | 189.02 Cr | 141.84 Cr | 199.82 Cr |
| Diluted EPS | 72.34 | 41.91 | 41.32 | 31.01 | 43.68 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Nov 2006 | Nov 2007 | Nov 2008 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 664.00 Cr | 676.00 Cr | 678.00 Cr | - | 2,422.32 Cr | 2,192.69 Cr | 2,281.00 Cr | 2,519.27 Cr |
| Cost of Revenue | - | - | - | - | 875.65 Cr | 795.23 Cr | 813.06 Cr | 887.16 Cr |
| Gross Profit | - | - | - | - | 1,546.67 Cr | 1,397.46 Cr | 1,467.94 Cr | 1,632.11 Cr |
| Operating Expenses | 537.00 Cr | 815.00 Cr | 760.00 Cr | - | 837.89 Cr | 820.40 Cr | 786.66 Cr | 785.02 Cr |
| Operating Income | 114.00 Cr | -149.00 Cr | -93.00 Cr | - | 708.78 Cr | 577.06 Cr | 681.28 Cr | 847.09 Cr |
| EBITDA | 127.00 Cr | -139.00 Cr | -82.00 Cr | - | 942.91 Cr | 823.76 Cr | 1,085.29 Cr | 1,042.88 Cr |
| Interest Expense | 0 | 0 | 0 | - | 13.39 Cr | 15.41 Cr | 8.41 Cr | 9.48 Cr |
| Pretax Income | 163.00 Cr | 451.00 Cr | 419.00 Cr | - | 824.01 Cr | 746.07 Cr | 1,016.09 Cr | 975.67 Cr |
| Tax Provision | 57.05 Cr | 112.75 Cr | 121.51 Cr | - | 200.08 Cr | 194.74 Cr | 248.49 Cr | 253.24 Cr |
| Net Income | 106.00 Cr | 340.00 Cr | 300.00 Cr | - | 623.93 Cr | 551.33 Cr | 767.60 Cr | 722.43 Cr |
| Diluted EPS | 35.64 | 113.94 | 100.39 | 133.89 | 136.38 | 120.51 | 167.79 | 157.92 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Nov 2006 | Nov 2007 | Nov 2008 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | 646.00 Cr | 867.00 Cr | 1,098.00 Cr | - | 4,000.73 Cr | 4,228.78 Cr | 4,911.11 Cr | 4,921.88 Cr |
| Current Assets | - | - | - | - | 2,525.09 Cr | 2,769.56 Cr | 3,512.85 Cr | 3,803.22 Cr |
| Cash & Equivalents | - | - | - | - | 36.60 Cr | 112.00 Cr | 495.07 Cr | 102.66 Cr |
| Inventory | - | - | - | - | 417.70 Cr | 433.69 Cr | 475.92 Cr | 472.66 Cr |
| Receivables | - | - | - | - | 151.73 Cr | 187.61 Cr | 193.09 Cr | 181.80 Cr |
| Total Liabilities | - | - | - | - | 793.43 Cr | 633.24 Cr | 693.70 Cr | 718.98 Cr |
| Current Liabilities | - | - | - | - | 657.35 Cr | 546.56 Cr | 569.51 Cr | 627.48 Cr |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | 0 | 0 | 0 | - | 134.47 Cr | 94.54 Cr | 108.40 Cr | 70.23 Cr |
| Total Equity | 406.00 Cr | 650.00 Cr | 901.00 Cr | - | 3,207.30 Cr | 3,595.54 Cr | 4,217.41 Cr | 4,202.90 Cr |
| Shares Outstanding | - | - | - | - | 4.57 Cr | 4.57 Cr | 4.57 Cr | 4.57 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Nov 2006 | Nov 2007 | Nov 2008 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 123.00 Cr | 17.00 Cr | 238.00 Cr | - | 355.68 Cr | 256.84 Cr | 659.75 Cr | 967.57 Cr |
| Investing Cash Flow | 7.00 Cr | 232.00 Cr | -79.00 Cr | - | -36.05 Cr | 53.70 Cr | -71.34 Cr | -561.67 Cr |
| Financing Cash Flow | -34.00 Cr | -76.00 Cr | -95.00 Cr | - | -345.79 Cr | -235.14 Cr | -205.34 Cr | -798.31 Cr |
| Capital Expenditure | -3.00 Cr | 266.00 Cr | -25.00 Cr | - | -64.98 Cr | -18.93 Cr | -28.15 Cr | -25.23 Cr |
| Free Cash Flow | 120.00 Cr | 283.00 Cr | 213.00 Cr | - | 290.70 Cr | 237.91 Cr | 631.60 Cr | 942.34 Cr |
| Net Change in Cash | 97.00 Cr | 173.00 Cr | 64.00 Cr | - | -26.16 Cr | 75.40 Cr | 383.07 Cr | -392.41 Cr |
Ratios (Annual)
Figures in %.
| Metric | Nov 2006 | Nov 2007 | Nov 2008 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 63.9% | 63.7% | 64.4% | 64.8% |
| Operating Margin % | 17.2% | -22.0% | -13.7% | - | 29.3% | 26.3% | 29.9% | 33.6% |
| Net Margin % | 16.0% | 50.3% | 44.2% | - | 25.8% | 25.1% | 33.7% | 28.7% |
| ROE % | 26.1% | 52.3% | 33.3% | - | 19.5% | 15.3% | 18.2% | 17.2% |
| ROCE % | - | - | - | - | 21.2% | 15.7% | 15.7% | 19.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PFIZER
Pfizer (PFE) Stock Looks Fully Priced After Its 21% Slump - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPSmxJRXdhd2M1Sm5jTnBJNnpxaWJYeC1GNlZUWVpKMW0tdW1mWVBOVHdUVmo0cmFLbmpQTElDRXVGNmV1b0RSanE1a0RHX1hVbkM3VE1McWlEcUNyYmlBMG83WXRzb245TTVhMVRYZVBxV2wyVlBMVEh3MlJpOGx1VE5IaklMbXdwc1RsSn…
Is Pfizer Inc. (PFE) A Good Stock To Buy Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOMk1TZ0EySmVsUmY0WXREekdZS2VQd1Q2dmpIRl8yX1dkdW8wMUIxTTFzN1FuTU9HUFZBQWJHOEd6ekU4QnNaZDZGVC1rRDVsaFdTUTVRZXBrLWxKSUM3Qi1xUXlwMGl0OWJ5NG01NWw3TkdraF80bVJuck1FTmNTbUxIWE84MWRVTkVieD…
Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried? - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxOU1N3RWRwOElyYUpuX1JYRHlZbnA3MmFPZGdOZ01leEtsOHB3aUhIWUtIOEVRUE9fekZzZVgwQkFwWlRFLWVmSEFMVDN6OFpqcjFSdWRWOTFJS1Q0bkptYm9aSWJMWWNxc0x1ekZsNVRUUlJYT0dfbjR1WXVRMWZnekRRLTJrd1lNQ3VmMW…
Guggenheim cuts Pfizer stock price target to $35 on model update - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOeVNqZkJZYVBxQ0JidXJoVXlnVExHUXdzZVdYZFBKRjdiTWtaZW9Hb1NBdlloM1lKU1YxMVlFTllNSC1nVFlsZkhyNG9md2VpcEw1ajRLYmZmQlU4SHdkb1BFc2NNRmpPTVhkZU5aUU9ya0g3eFlieHMyYld4ZGZ5TTV5MjUzVmVsTC1Jbn…
Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen - 24/7 Wall St.
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQWnVOdmllNTFtWHh2VkUyZjNnU2NlU1N5dU9COGN6WjVFaWRTSlVKNHR2Q2I0aElJU2g4SkFDOHdFc2x0UHhSRi04RVpwYmJkazBtWHI5UWZ3NkNHYVBoa3BsYy1LRWUtRF9kSGdBZlNMTDVPdnlKVzQ2RTVjMnk2NWRXNzJBWXBnalRmbl…
PFE Stock Continues To Drop As Lung Cancer Trial Disappointment Overshadows Ibrance Win - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxQdFhnbWwyTFZLSURtM2RDNVZxY3FxemQ1N1A4Ym5RSDlubW91YnBONHlxRjdqdjV2ZjNKaFYwakQ0VVRlXzhrUVlSYnIyZjdxZWY4VGtOdVRscDExT1IyLW1zSlhMOHZpNFl3b0N3YUxJTU9rbC1kV2FQV3hsYndwUlpRaGdEeHFSTWRuN2…
PFIZER — Frequently Asked Questions
What is the current share price of Pfizer Limited (PFIZER)?
As of 2026-07-15 09:52 IST, Pfizer Limited (PFIZER) trades at ₹4,713.00 on NSE. Its 52-week range is ₹4,404.90 to ₹5,766.50.
What is the market capitalisation of PFIZER?
Pfizer Limited (PFIZER) has a market capitalisation of ₹21,560.91 Cr on NSE.
What is the P/E ratio of PFIZER?
PFIZER trades at a trailing price-to-earnings (P/E) ratio of 29.84. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 5.16.
Does PFIZER pay a dividend?
Pfizer Limited (PFIZER) currently offers a dividend yield of 1.59%.
What is the return on equity (ROE) of PFIZER?
PFIZER has a return on equity (ROE) of 17.19%. Its return on capital employed (ROCE) is 22.94%.
Is PFIZER a good stock to buy?
This page provides a data-driven analysis of Pfizer Limited (PFIZER), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.